Medications

US approves new drug to treat Alzheimer's disease

The US Food and Drug Administration on Friday approved a highly anticipated new drug designed to slow cognitive decline in patients in mild and early stages of Alzheimer's disease.

Neuroscience

Targeting tau, the other protein behind Alzheimer's disease

In November, researchers reported the drug lecanemab slowed the progression of Alzheimer's disease. The effect was modest, but it has generated tremendous excitement because it was the first time a drug had been shown to ...

Alzheimer's disease & dementia

Drug slows Alzheimer's but can it make a real difference?

An experimental Alzheimer's drug modestly slowed the brain disease's inevitable worsening—but the anxiously awaited new data leaves unclear how much difference that might make in people's lives.

Neuroscience

Researchers discover how immune cells prevent cognitive decline

Could the underproduction of poorly understood immune cells contribute to Alzheimer's disease and other forms of cognitive decline? A Rutgers study in Nature Immunology suggests it may—and that increasing these cells could ...

page 8 from 40